Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease:: Results of two double-blind, randomized studies

被引:39
作者
Bochenek, WJ
Peters, S
Fraga, PD
Wang, WJ
Mack, ME
Osato, MS
El-Zimaity, HMT
Davis, KD
Graham, DY
机构
[1] Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Wyeth Res, Philadelphia, PA USA
关键词
pantoprazole; Helicobacter pylori; eradication; antibiotics; 7-day triple therapy;
D O I
10.1111/j.1523-5378.2003.00179.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim. To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease. Methods. H. pylori infection was identified by rapid urease (CLOtest), and confirmed by histology and culture. Patients were enrolled into one of two randomized, double-blind, multicenter, parallel-group studies. In study A, patients received oral pantoprazole 40 mg, clarithromycin 500 mg, and metronidazole 500 mg (PCM); pantoprazole, clarithromycin and amoxicillin 1000 mg (PCA); or pantoprazole and clarithromycin (PC). In study B, patients received PCM, PCA, PC, or clarithromycin and metronidazole without pantoprazole (CM). Treatments were given twice daily for 7 days. H. pylori status after therapy was assessed by histology and culture at 4 weeks after completing the course of study treatment. Modified intent-to-treat (MITT; each study: n = 424, n = 512) and per-protocol (PP; each study: n = 371, n = 454) populations were analyzed. The MITT population comprised all patients whose positive H. pylori status was confirmed by culture and histology; the PP population comprised patients who also complied with greater than or equal to 85% of study medication doses. Results. A total of 1016 patients were enrolled. Cure rates among patients with clarithromycin-susceptible H. pylori strains were 82 and 86% for PCM, and 72 and 71% for PCA, in studies A and B, respectively. Cure rates among patients with metronidazole-susceptible H. pylori strains were 82 and 87% for PCM, and 71 and 69% for PCA, in studies A and B, respectively. The combined eradication rates observed with the PCM regimen were superior to those of all other regimens tested. Side-effects were infrequent and mild. Conclusions. PCM had the highest overall eradication rate in these two studies examining 7-day treatment regimens. All regimens were safe and well tolerated.
引用
收藏
页码:626 / 642
页数:17
相关论文
共 128 条
  • [71] Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x
  • [72] Helicobacter pylori eradication and gastric ulcer healing -: comparison of three pantoprazole-based triple therapies
    Malfertheiner, P
    Kirchner, T
    Kist, M
    Leodolter, A
    Peitz, U
    Strobel, S
    Bohuschke, M
    Gatz, G
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (09) : 1125 - 1135
  • [73] Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure
    Matsuoka, M
    Yoshida, Y
    Hayakawa, K
    Fukuchi, S
    Sugano, K
    [J]. GUT, 1999, 45 (04) : 503 - 507
  • [74] Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial:: the MACH 2 study
    Mégraud, F
    Lehn, N
    Lind, T
    Bayerdörffer, E
    O'Morain, C
    Spiller, R
    Unge, P
    Van Zanten, SV
    Wrangstadh, M
    Burman, CF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) : 2747 - 2752
  • [75] Megraud F, 1997, J Physiol Pharmacol, V48 Suppl 4, P25
  • [76] Risk factors for Helicobacter pylori resistance in the United States:: The surveillance of H-pylori antimicrobial resistance partnership (SHARP) study, 1993-1999
    Meyer, JM
    Silliman, NP
    Wang, WJ
    Siepman, NY
    Sugg, JE
    Morris, D
    Zhang, J
    Bhattacharyya, H
    King, EC
    Hopkins, RJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 136 (01) : 13 - 24
  • [77] Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H-pylori infection -: A multiple logistic regression analysis
    Miwa, H
    Misawa, H
    Yamada, T
    Nagahara, A
    Ohtaka, K
    Sato, N
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (11) : 2445 - 2450
  • [78] O'Connor HJ, 1998, ALIMENT PHARM THERAP, V12, P273
  • [79] Macrolide resistance in Helicobacter pylori: Rapid detection of point mutations and assays of macrolide binding to ribosomes
    Occhialini, A
    Urdaci, M
    DoucetPopulaire, F
    Bebear, CM
    Lamouliatte, H
    Megraud, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) : 2724 - 2728
  • [80] Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States
    Osato, MS
    Reddy, R
    Reddy, SG
    Penland, RL
    Malaty, HM
    Graham, DY
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (09) : 1217 - 1220